Live varicella vaccine polarizes the mucosal adjuvant action of cholera toxin or its B subunit on specific Th1-type helper T cells with a single nasal coadministration in mice

Journal of Medical Virology

Volumn 70, Issue 2, 2003, Pages 329-335

  Sasaki, Keiko ^a   Kato, Michio ^a   Takahashi, Tsuyoshi ^a   Ochi, Sadayuki ^a   Ichinose, Yoshio ^b   Shiraki, Kimiyasu ^c   Asano, Yoshizo ^a   Iwanaga, Masaaki ^d   Tsuji, Takao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

^d UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

B subunit of cholera toxin; Cholera toxin; Mucosal adjuvant; Oka vaccine; Th1 Th2type T cell

Indexed keywords

ADJUVANT; CHICKENPOX VACCINE; CHOLERA TOXIN; CHOLERA TOXIN B SUBUNIT; ESCHERICHIA COLI ENTEROTOXIN; INTERLEUKIN 2; INTERLEUKIN 4; LIVE VACCINE; NEUTRALIZING ANTIBODY; PROTEIN SUBUNIT; THYMIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BACTERIUM MUTANT; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; MOUSE; NONHUMAN; NOSE MUCOSA; SPLEEN CELL; TH1 CELL; TH2 CELL; VARICELLA ZOSTER VIRUS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; CHICKENPOX; CHICKENPOX VACCINE; CHOLERA TOXIN; FEMALE; IMMUNITY, MUCOSAL; IMMUNIZATION; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; TH1 CELLS;

ESCHERICHIA COLI;

EID: 0037410249     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10399     Document Type: Article

References (38)

1. Asano Y, Yoshikawa T, Suga S, Kobayashi I, Nakashima T, Yazaki T, Ozaki T, Yamada A, Imanishi J. 1993. Postexposure prophylaxis of varicella in family contact by oral acyclovir. Pediatrics 92: 219-222.
2. Berger R, Luescher D, Just M. 1984. Enhancement of varicella-zosterspecific immune responses in the elderly by boosting with varicella vaccine. J Infect Dis 149:647.
3. Bowen JC, Nair SK, Reddy R, Rouse BT. 1994. Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens. Immunology 81:338-342.
4. Bromander A, Holmgren J, Lycke N. 1991. Cholera toxin stimulates IL1 production and enhances antigen presentation by macrophages in vitro. J Immunol 146:2908-2914.
5. Brunell PA, Ross A, Miller LH, Kuo B. 1969. Prevention of varicella by zoster immune globulin. N Engl J Med 29;280:1191-1194.
6. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184:747-752.
7. Cong Y, Weaver CT, Elson CO. 1997. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression. J Immunol 159:5301-5308.
8. Cong Y, Oliver AO, Elson CO. 2001. Effects of cholera toxin on macrophage production of costimulatory cytokines. Eur J Immunol 31:64-71.
9. Foss DL, Zilliox MJ, Murtaugh MP. 1999. Differential regulation of macrophage interleukin-1 (IL-1), IL-12, and CD80-CD86 by two bacterial toxins. Infect Immun 67:5275-5281.
10. Gagliardi MC, Sallusto F, Marinaro M, Langenkamp A, Lanzavecchia A, De Magistris MT. 2000. Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming. Eur J Immunol 30:2394-2403.
11. Gershon AA, Steinberg S, Brunell PA. 1974. Zoster immune globulin. A further assessment. N Engl J Med 290:243-245.
12. Gershon AA, LaRussa P, Hardy I, Steinberg S, Silverstein S. 1992. Varicella vaccine: the American experience. J Infect Dis 166 (suppl):S63-68.
13. Hagiwar Y, Tsuji T, Iwasaki T, Kadowaki S, Asanuma H, Chen Z, Komase K, Suzuki Y, Aizawa C, Kurata T, Tamura S. 2001. Effectiveness and safety of mutant Escherichia coli heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine. Vaccine 19:2071-2079.
14. Hayward A, Levin M, Wolf W, Angelova G, Gilden D. 1991. Varicellazoster virus-specific immunity after herpes zoster. J Infect Dis 163: 873-875.
15. Hornquist E, Lycke N. 1993. Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur J Immunol 23:2136-2143.
16. Iwanaga M, Yamamoto K, Higa N, Ichinose Y, Nakasone N, Tanabe M. 1986. Culture conditions for stimulating cholera toxin production by Vibrio cholerae O1 E1 Tor. Microbiol Immunol 30:1075-1083.
17. Kamiya N, Asano Y, Yoshino J, Sasaki K, Honma Y, Kawase H, Yokochi T, Shiraki K, Tsuji T. 2001. Long-term persistence of cellular immunity to Oka vaccine virus induced by pernasal co-administration with Escherichia coli enterotoxin in mice. Vaccine 30:3131-3136.
18. Kamogawa Y, Minasi LA, Carding SR, Bottomly K, Flavell RA. 1993. The relationship of IL-4- and IFN gamma-producing T cells studied by lineage ablation of IL-4-producing cells. Cell 75:985-995.
19. Kikuta K, Kurata H, Nagamine T, Aizawa C, Ueno Y, Kurata T, Tamura S. 1990. Enhancement of DTH response by cholera toxin B subunit inoculated intranasally together with influenza HA vaccine. Microbiol Immunol 34:337-346.
20. Krause PR, Klinman DM. 2000. Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nat Med 6:451-454.
21. McGee DW, Elson CO, McGhee JR. 1993. Enhancing effect of cholera toxin on interleukin-6 secretion by IEC-6 intestinal epithelial cells: mode of action and augmenting effect of inflammatory cytokines. Infect Immun 61:4637-4644.
22. Mosmann TR, Coffman RL. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145-173.
23. Myers MG, Connelly BL. 1992. Animal models of varicella. J Infect Dis 166:S48-50.
24. Nakagawa I, Takahashi I, Kiyono H, McGhee JR, Hamada S. 1996. Oral immunization with the B subunit of the heat-labile enterotoxin of Escherichia coli induces early Th1 and late Th2 cytokine expression in Peyer's patches. J Infect Dis 173:1428-1436.
25. + Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses. Infect Immun 64:1516-1525.
26. Sasaki K, Asano Y, Honma Y, Kamiya N, Handa T, Ichinose Y, Yokochi T, Shiraki K, Tsuji T. 2001. Adjuvant action of Escherichia coli enterotoxin for delayed-type hypersensitivity to Oka vaccine virus on pernasal co-administration in mice. Vaccine 19:931-936.
27. Sato H, Kageyama S, Imakita M, Ida M, Yamamura J, Kurokawa M, Shiraki K. 1998. Immune response to varicella-zoster virus glycoproteins in guinea pigs infected with Oka varicella vaccine. Vaccine 16:1263-1269.
28. Straus SE, Ostrove JM, Inchauspe G, Felser JM, Freifeld A, Croen KD, Sawyer MH. 1998. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. Ann Intern Med 109:438-439.
29. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. 1974. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 2:1288-1290.
30. Takahashi I, Marinaro M, Kiyono H, Jackson RJ, Nakagawa I, Fujihashi K, Hamada S, Clements JD, Bost KL, McGhee JR. 1996. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis 173:627-635.
31. Tamura S, Samegai Y, Kurata H, Kurata T. 1988. Effects of cholera toxin on delayed-type hypersensitivity to sheep red blood cells inoculated intranasally into mice. Microbiol Immunol 32:1145- 1161.
32. Trannoy E, Berger R, Hollander G, Bailleux F, Heimendinger P, Vuillier D, Creusvaux H. 2000. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine 18: 1700-1706.
33. Tsuji T, Yokochi T, Kamiya H, Kawamoto Y, Miyama A, Asano Y. 1997. Relationship between a low toxicity of the mutant A subunit of enterotoxigenic Escherichia coli enterotoxin and its strong adjuvant action. Immunology 90:176-182.
34. Tsuji T, Shiraki K, Sato H, Yue-Mea J, Honma Y, Yoshikawa T, Asano Y. 2000. Humoral immunoresponse to varicella-zoster virus pernasally coadministered with Escherichia coli enterotoxin in mice. Vaccine 18:2049-2054.
35. Vajdy M, Kosco-Vilbois MH, Kopf M, Kohler G, Lycke N. 1993. Impaired mucosal immune responses in interleukin 4-targeted mice. J Exp Med 181:41-53.
36. Watson B, Rothstein E, Bernstein H, Arbeter A, Arvin A, Chartrand S, Clements D, Kumar ML, Reisinger K, Blatter M, et al. 1995. Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J Infect Dis 172:217-219.
37. Xu-Amano J, Kiyono H, Jackson RJ, Staats HF, Fujihashi K, Burrows PD, Elson CO, Pillai S, McGhee JR. 1993. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med 178:1309-1320.
38. Zerboni L, Nader S, Aoki K, Arvin AM. 1998. Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. J Infect Dis 177:1701-1704.